Keloids and hypertrophic scars · Lab and clinical study · 2024
Can shockwave help keloids and raised scars?
This review gathered 12 studies on shockwave for keloids and raised (hypertrophic) scars. Keloids improved with shockwave alone and with steroid injections, with no clear difference, and adding shockwave to injections improved scar scores more. Several studies reported thinner, less itchy or less painful raised scars.
Possible early help for raised scars- keloid trials
- 2
- studies of raised (hypertrophic) scars
- 7
- lab studies in rabbits or cells
- 3
Good to know: Studies used different treatment plans and scar measures.
Gili N, Micallef Stafrace K, Laybats F, et al. Cureus, 2024 · Read the paper ↗
The treatment
- Keloid clinical protocols
- Wang: 3 sessions over 6 weeks; lesion-area-dependent impulses (area in cm² × 8, minimum 500); 0.11 mJ/mm², 4 Hz; generator type not specified, dermPACE. Kim: weekly for 10 weeks; 500 impulses/cm²; 0.29 mJ/mm²; 250 pulses/min (4.2 Hz); generator type not specified, dermPACE. Intralesional triamcinolone was the comparator in Wang (10 mg, three sessions at two-weekly intervals) and was given to both groups in Kim (10 mg per 1 cm² of lesion, four sessions at three-weekly intervals).
- Hypertrophic scar clinical protocol range
- Raw Table 5 lists 3–10 sessions, one per week (Fioramonti and Zaghloul: two per week for 6 weeks), 100–3,000 pulses/session or 30–50, 100 (1,000–2,000/session) or 350 ± 10 pulses/cm², EFD 0.037–0.30 mJ/mm² when reported, and 4–6 Hz. Zaghloul energy/frequency are not stated. Focused/radial type is mostly unspecified; one Joo row is labeled focused. Do not homogenize these regimens.
- Chuangsuwanich 2022
- One session weekly for 6 weeks; 350±10 pulses/cm²; 0.1 mJ/mm²; 4 Hz; focused/radial status not specified; Dermagold 100.
- Fioramonti 2012
- Two sessions weekly for 6 weeks; 100 pulses; 0.037 mJ/mm²; 4 Hz; modality not specified; Evotron.
- Moorgart 2020
- One session weekly for 10 weeks; 30–50 pulses/cm²; 0.25 mJ/mm²; 6 Hz; modality not specified; Duolith-SD1 T-Top.
- Zaghloul 2016
- Two sessions weekly for 6 weeks; 2,500–3,000 pulses; energy, frequency, modality and instrument not specified.
- Lee 2021
- One session weekly for 6 weeks; 100 pulses/cm² (1,000–2,000 per session); 0.05–0.30 mJ/mm²; 4 Hz; modality not specified; Duolith SD-1.
- Joo 2020
- One session weekly for 4 weeks; 100 pulses/cm² (1,000–2,000 per session); 0.05–0.30 mJ/mm²; 4 Hz; modality not specified; Duolith SD-1.
- Joo 2018
- One session weekly for 3 weeks; 100 pulses/cm² (1,000–2,000 per session); 0.05–0.20 mJ/mm²; 4 Hz; focused; Duolith SD-1.
- Zhao 2018 [36] — rabbits
- One session weekly for 4 weeks; 500 pulses; low-energy ESWT 0.1 mJ/mm² and high-energy 0.2 mJ/mm²; 8 Hz; modality not specified; Swiss DolClast Classic.
- Cui 2018 [37] — cell culture
- One session; 1,000 pulses; 0.03, 0.1 or 0.3 mJ/mm²; 4 Hz; focused; Duolith SD-1.
- Zhao 2018 [38] — rabbits
- One session weekly for 4 weeks; 500 pulses; low-energy 0.1 mJ/mm² and high-energy 0.18 mJ/mm²; 8 Hz; radial; Swiss DolClast Classic.
Who took part
People with keloids or raised scars in 2 keloid trials and 7 scar studies, plus 3 studies in rabbits or cells.
Side effects
The review does not report side effects.
All the numbers and the full appraisal
What the full paper reports.
Systematic review of pathological scars: 2 keloid randomized trials; 7 hypertrophic-scar clinical studies; 3 preclinical studies (2 rabbit experiments, 1 fibroblast culture). Human and experimental samples are not additive.
Study-level narrative synthesis9 reported outcomes
Included clinical and preclinical reports
Study-level narrative synthesis Narrative synthesis
The review reports 12 articles: 2 keloid RCTs and 10 hypertrophic-scar reports, comprising 7 clinical studies and 3 preclinical studies (2 rabbit experiments and 1 fibroblast-culture study). Human and experimental units are distinct and must not be combined. Table 4 has a participant-count inconsistency for Lee et al. (2021): 25 ESWT + 28 control = 53, although the table states 48.
Analysis details and source
Review-level extraction; underlying primary papers were not independently inspected. No pooled estimate is claimed. Human clinical and preclinical findings remain separate.
Keloid ESWT versus steroid injection
Study-level narrative synthesis Narrative synthesis
Wang et al. randomized 39 patients (22 ESWT, 17 intralesional steroid). Both groups improved lesion area/volume, pain and POSAS scores from baseline, but between-group tests were nonsignificant: pain p=0.429, POSAS patient p=0.55, observer p=0.25. These results do not establish equivalence.
Analysis details and source
Review-level extraction; underlying primary papers were not independently inspected. No pooled estimate is claimed. Human clinical and preclinical findings remain separate.
ESWT added to steroid for keloids
Study-level narrative synthesis Narrative synthesis
Kim et al. compared ESWT plus steroid (n=20) with steroid alone (n=20). VSS declined 56.13%±18.12% versus 40.15%±14.09%; the greater decline in the adjunct group was significant (p=0.003). Lesion length, width and height also decreased in both groups, with greater percentage reductions reported for ESWT plus steroid. This tests add-on therapy, not steroid replacement.
Analysis details and source
Review-level extraction; underlying primary papers were not independently inspected. No pooled estimate is claimed. Human clinical and preclinical findings remain separate.
Hypertrophic-scar thickness
Study-level narrative synthesis Narrative synthesis
Zaghloul et al. reported mean ultrasound thickness reduction of 2.86 mm (42.55%) with ESWT versus 0.8 mm (12%) with placebo; between-group p=0.0001. Joo et al. and Lee et al. also reported significant thickness reduction (p=0.018 and p=0.03, respectively). The review does not provide confidence intervals or complete arm summaries in the accessible text.
Analysis details and source
Review-level extraction; underlying primary papers were not independently inspected. No pooled estimate is claimed. Human clinical and preclinical findings remain separate.
Hypertrophic-scar scores and appearance
Study-level narrative synthesis Narrative synthesis
Findings varied by instrument: Chuangsuwanich and Moorgart reported significant POSAS improvements; Zaghloul reported VSS mean decrease 4.25 (48.57%). Joo found vascularity improvement (p=0.0015) but no significant total VSS change (p=0.19). Erythema findings conflicted (Lee p=0.03; Chuangsuwanich p=0.7; Moorgart nonsignificant); melanin index was nonsignificant in Chuangsuwanich (p=0.87) and Lee (p=0.62). The review also reports Moorgart vertical elasticity improvement, with no significant TEWL change; Lee sebum and erythema improved but TEWL, skin elasticity and melanin did not; Chuangsuwanich erythema and melanin did not improve.
Analysis details and source
Review-level extraction; underlying primary papers were not independently inspected. No pooled estimate is claimed. Human clinical and preclinical findings remain separate.
Hypertrophic-scar symptoms and function
Study-level narrative synthesis Narrative synthesis
Joo et al. (2020) reported significant pain improvement (p=0.001), and Joo et al. (2018) reported itch-frequency/duration/severity/consequence improvements (all p<0.05). Significant improvement was reported in two hand-function subtasks; other subtasks did not change significantly. The text cites this hand-function result to reference [35] (Joo 2018), but Tables 4 and 8 list hand function under Joo et al. (2020) [34]. Fioramonti reported subjective VAS appearance improvement without statistical analysis. These findings come from different studies and should not be treated as one combined effect.
Analysis details and source
Review-level extraction; underlying primary papers were not independently inspected. No pooled estimate is claimed. Human clinical and preclinical findings remain separate.
Preclinical scar biology and morphology
Study-level narrative synthesis Narrative synthesis
Two rabbit experiments and one fibroblast-culture study reported changes in scar elevation index, collagen arrangement, fibroblast density, TGF-β1, α-SMA, extracellular-matrix markers, Smad signaling, wrinkles or hemoglobin. These are animal/cellular findings, not clinical patient outcomes. Table 8 says the 2018 rabbit study found no significant effect on scar diameter, area, elevation/volume or melanin. Table 8 specifies that Zhao [36] found significant changes in collagen-fiber arrangement, fibroblast density and scar-elevation index; Cui [37] reported significant TGF-β1, α-SMA, collagen I/III, fibronectin and protein-expression changes; Zhao [38] reported significant hemoglobin, TGF-β/Smad and wrinkle findings, but null diameter, area, elevation/volume and melanin results.
Analysis details and source
Review-level extraction; underlying primary papers were not independently inspected. No pooled estimate is claimed. Human clinical and preclinical findings remain separate.
Reported ESWT protocols
Study-level narrative synthesis Narrative synthesis
Keloid regimens: Wang, 3 sessions over 6 weeks, lesion-area-dependent impulses (area cm² ×8; minimum 500), 0.11 mJ/mm², 4 Hz; Kim, weekly for 10 weeks, 500 impulses/cm², 0.29 mJ/mm², 250 pulses/min (4.2 Hz). Hypertrophic clinical protocols varied from 3 to 10 weeks (3 to 12 sessions); raw Tables 5 and 7 specify study-level doses, including one study with energy/frequency not reported. Most devices were not identified as radial/focused.
Analysis details and source
Review-level extraction; underlying primary papers were not independently inspected. No pooled estimate is claimed. Human clinical and preclinical findings remain separate.
Adverse events
Study-level narrative synthesis Narrative synthesis
The accessible main text provides no systematic adverse-event results for the scar trials. Its discussion lists known steroid-injection risks but does not quantify ESWT harms. Do not infer that ESWT was harmless.
Analysis details and source
Review-level extraction; underlying primary papers were not independently inspected. No pooled estimate is claimed. Human clinical and preclinical findings remain separate.
Study-specific outcomes as classified in Table 812 reported outcomes
Wang et al. (2018), keloid RCT
Study-specific outcomes as classified in Table 8 Narrative result; no effect estimate supplied in this table
Significant changes were reported in collagen I, Masson’s trichrome, collagen III and MMP-13. No statistically significant improvement was reported in blood-flow perfusion, cell activity, proliferation, apoptosis/concentration, angiogenesis, or proliferative, anti-inflammatory or apoptosis biomarkers. Patient and observer POSAS functional outcomes improved; total lesion surface area and volume decreased; patient and observer POSAS aesthetic outcomes improved.
Analysis details and source
Table 8 qualitative significance statements are reproduced without inventing p values or effect magnitudes. Clinical and preclinical evidence is kept separate.
Kim et al. (2020), keloid RCT
Study-specific outcomes as classified in Table 8 Narrative result; no effect estimate supplied in this table
Table 8 states biological outcomes were not assessed. Lesion length, width, height and VSS improved significantly.
Analysis details and source
Table 8 qualitative significance statements are reproduced without inventing p values or effect magnitudes. Clinical and preclinical evidence is kept separate.
Chuangsuwanich et al. (2022), hypertrophic scar RCT
Study-specific outcomes as classified in Table 8 Narrative result; no effect estimate supplied in this table
Patient and observer POSAS functional outcomes and POSAS aesthetic outcomes improved significantly; erythema and melanin indices did not improve significantly.
Analysis details and source
Table 8 qualitative significance statements are reproduced without inventing p values or effect magnitudes. Clinical and preclinical evidence is kept separate.
Fioramonti et al. (2012), hypertrophic scar, prospective observational study
Study-specific outcomes as classified in Table 8 Narrative result; no effect estimate supplied in this table
Appearance improved on VAS, with no statistical analysis available. Biological and functional outcomes were not assessed.
Analysis details and source
Table 8 qualitative significance statements are reproduced without inventing p values or effect magnitudes. Clinical and preclinical evidence is kept separate.
Moorgart et al. (2020), hypertrophic scar RCT
Study-specific outcomes as classified in Table 8 Narrative result; no effect estimate supplied in this table
Vertical elasticity and patient/observer POSAS functional outcomes improved significantly. Transepidermal water loss (TEWL) did not improve significantly. POSAS aesthetic outcomes improved; color did not change significantly.
Analysis details and source
Table 8 qualitative significance statements are reproduced without inventing p values or effect magnitudes. Clinical and preclinical evidence is kept separate.
Zaghloul et al. (2016), hypertrophic scar RCT
Study-specific outcomes as classified in Table 8 Narrative result; no effect estimate supplied in this table
Table 8 reports significant improvement in ultrasound-measured scar thickness and VSS; biological and functional outcomes were not assessed.
Analysis details and source
Table 8 qualitative significance statements are reproduced without inventing p values or effect magnitudes. Clinical and preclinical evidence is kept separate.
Lee et al. (2021), hypertrophic scar RCT
Study-specific outcomes as classified in Table 8 Narrative result; no effect estimate supplied in this table
Sebum, scar thickness and erythema improved significantly. TEWL, skin elasticity and melanin index did not improve significantly; functional outcomes were not assessed.
Analysis details and source
Table 8 qualitative significance statements are reproduced without inventing p values or effect magnitudes. Clinical and preclinical evidence is kept separate.
Joo et al. (2020), hypertrophic scar RCT
Study-specific outcomes as classified in Table 8 Narrative result; no effect estimate supplied in this table
Skin vascularity, pain, scar thickness and VAS improved significantly; Table 8 lists hand function as improved without stating significance. Scar pigmentation and total VSS did not improve significantly.
Analysis details and source
Table 8 qualitative significance statements are reproduced without inventing p values or effect magnitudes. Clinical and preclinical evidence is kept separate.
Joo et al. (2018), hypertrophic scar RCT
Study-specific outcomes as classified in Table 8 Narrative result; no effect estimate supplied in this table
NRS, laser-Doppler blood-perfusion imaging, 5-D Itch Scale and Leuven Itch Scale improved significantly. Aesthetic outcomes were not assessed.
Analysis details and source
Table 8 qualitative significance statements are reproduced without inventing p values or effect magnitudes. Clinical and preclinical evidence is kept separate.
Zhao et al. (2018) [36], preclinical rabbit study
Study-specific outcomes as classified in Table 8 Narrative result; no effect estimate supplied in this table
Collagen-fiber arrangement, fibroblast density and scar-elevation index improved significantly. These are not clinical outcomes in people.
Analysis details and source
Table 8 qualitative significance statements are reproduced without inventing p values or effect magnitudes. Clinical and preclinical evidence is kept separate.
Cui et al. (2018) [37], preclinical fibroblast culture
Study-specific outcomes as classified in Table 8 Narrative result; no effect estimate supplied in this table
TGF-β1, α-SMA, collagen I and III, fibronectin and protein expression improved significantly. Functional and aesthetic outcomes were not assessed.
Analysis details and source
Table 8 qualitative significance statements are reproduced without inventing p values or effect magnitudes. Clinical and preclinical evidence is kept separate.
Zhao et al. (2018) [38], preclinical rabbit study
Study-specific outcomes as classified in Table 8 Narrative result; no effect estimate supplied in this table
Hemoglobin, TGF-β1, Smad2, Smad3, Smad7 and scar wrinkles improved significantly. Scar diameter, area, elevation/volume and melanin did not improve significantly. These are preclinical findings.
Analysis details and source
Table 8 qualitative significance statements are reproduced without inventing p values or effect magnitudes. Clinical and preclinical evidence is kept separate.
How treatment was delivered
Wang: 3 sessions over 6 weeks; lesion-area-dependent impulses (area in cm² × 8, minimum 500); 0.11 mJ/mm², 4 Hz; generator type not specified, dermPACE. Kim: weekly for 10 weeks; 500 impulses/cm²; 0.29 mJ/mm²; 250 pulses/min (4.2 Hz); generator type not specified, dermPACE. Intralesional triamcinolone was the comparator in Wang (10 mg, three sessions at two-weekly intervals) and was given to both groups in Kim (10 mg per 1 cm² of lesion, four sessions at three-weekly intervals).
Raw Table 5 lists 3–10 sessions, one per week (Fioramonti and Zaghloul: two per week for 6 weeks), 100–3,000 pulses/session or 30–50, 100 (1,000–2,000/session) or 350 ± 10 pulses/cm², EFD 0.037–0.30 mJ/mm² when reported, and 4–6 Hz. Zaghloul energy/frequency are not stated. Focused/radial type is mostly unspecified; one Joo row is labeled focused. Do not homogenize these regimens.
One session weekly for 6 weeks; 350±10 pulses/cm²; 0.1 mJ/mm²; 4 Hz; focused/radial status not specified; Dermagold 100.
Two sessions weekly for 6 weeks; 100 pulses; 0.037 mJ/mm²; 4 Hz; modality not specified; Evotron.
One session weekly for 10 weeks; 30–50 pulses/cm²; 0.25 mJ/mm²; 6 Hz; modality not specified; Duolith-SD1 T-Top.
Two sessions weekly for 6 weeks; 2,500–3,000 pulses; energy, frequency, modality and instrument not specified.
One session weekly for 6 weeks; 100 pulses/cm² (1,000–2,000 per session); 0.05–0.30 mJ/mm²; 4 Hz; modality not specified; Duolith SD-1.
One session weekly for 4 weeks; 100 pulses/cm² (1,000–2,000 per session); 0.05–0.30 mJ/mm²; 4 Hz; modality not specified; Duolith SD-1.
One session weekly for 3 weeks; 100 pulses/cm² (1,000–2,000 per session); 0.05–0.20 mJ/mm²; 4 Hz; focused; Duolith SD-1.
One session weekly for 4 weeks; 500 pulses; low-energy ESWT 0.1 mJ/mm² and high-energy 0.2 mJ/mm²; 8 Hz; modality not specified; Swiss DolClast Classic.
One session; 1,000 pulses; 0.03, 0.1 or 0.3 mJ/mm²; 4 Hz; focused; Duolith SD-1.
One session weekly for 4 weeks; 500 pulses; low-energy 0.1 mJ/mm² and high-energy 0.18 mJ/mm²; 8 Hz; radial; Swiss DolClast Classic.
The review does not present systematic adverse-event results for ESWT in the included scar trials. Do not infer safety from silence. Steroid risks discussed by authors are contextual, not comparative harm data.
Only 12 articles were included; studies had small samples and heterogeneous designs, protocols and outcomes. Long-term follow-up was limited and publication bias was not formally assessed.
Table 4 reports 48 subjects for Lee et al. (2021), but lists 25 ESWT and 28 control, totaling 53. The review does not resolve this discrepancy.
Keloid monotherapy results reported no significant between-group differences, while discussion calls outcomes comparable; no equivalence margin or precision interval is supplied. Add-on ESWT was a different comparison.
Findings checked against the full source by a separate automated reviewer.
Limitations noted by the reviewers
- Only 12 articles were included; studies had small samples and heterogeneous designs, protocols and outcomes. Long-term follow-up was limited and publication bias was not formally assessed.
- Table 4 reports 48 subjects for Lee et al. (2021), but lists 25 ESWT and 28 control, totaling 53. The review does not resolve this discrepancy.
- Keloid monotherapy results reported no significant between-group differences, while discussion calls outcomes comparable; no equivalence margin or precision interval is supplied. Add-on ESWT was a different comparison.
Source-linked critical reading
Systematic review of human and preclinical studies
Technical source record
Complete article and raw Tables 1–8 read including all study rows, protocols, numeric outcomes and discrepancies; all four captions and limitations/discussion/conclusions checked.
Early evidence suggests possible benefit for selected scar outcomes, but it does not establish a standard ESWT protocol or prove replacement of steroid treatment. Some evidence is preclinical only.
What clinical and preclinical evidence exists for ESWT in keloid and hypertrophic scars?
Systematic literature review using PRISMA methods; 12 included articles, with no meta-analysis. Risk-of-bias tools varied by trial design and species.
Two keloid RCTs (39 and 40 patients); seven hypertrophic-scar clinical reports plus three preclinical studies (two rabbit experiments and one cell culture). Do not combine human and preclinical units.
Clinical regimens varied by scar and study. Keloid protocols included 3 sessions over 6 weeks at 0.11 mJ/mm² and weekly sessions for 10 weeks at 0.29 mJ/mm². Hypertrophic protocols and details varied; see reported ranges and missing fields.
Keloid studies compared ESWT with intralesional steroid or ESWT plus steroid with steroid alone. Hypertrophic studies used sham/control or before-after designs.
Keloid monotherapy and steroid groups both improved, without significant between-group differences. Adding ESWT to steroid improved VSS more than steroid alone (56.13%±18.12% vs 40.15%±14.09%; p=0.003). Hypertrophic findings varied by score/feature; thickness decreased in several studies. Animal/cell markers are not patient outcomes. The nine clinical and three preclinical rows of Table 8 are now represented separately, including study-level positive and null biological, functional and aesthetic findings; the seven hypertrophic-scar and three preclinical dose rows are transcribed individually from Tables 5 and 7.
Nonsignificant ESWT-versus-steroid results do not prove equivalence. Add-on ESWT versus steroid alone tests augmentation, not replacement. One table contains a participant-count inconsistency (Lee: 25+28 versus stated 48).
No systematic trial-level ESWT adverse-event results are available in the main text. Lack of reporting is not evidence of no harms.
Small evidence base, varied designs/outcomes/protocols, limited long-term follow-up, no meta-analysis and publication bias not formally assessed. Table 4 count for Lee et al. is internally inconsistent.
Potentially relevant to symptom and scar-feature research, but effect certainty, recurrence, durability and optimal protocol remain unclear. Experimental biology cannot establish patient benefit.
Larger preregistered trials should separate keloids from hypertrophic scars, standardize scar measures and protocol, report between-group estimates/intervals and harms, and follow recurrence over time.
Read the original article.
The Role of Extracorporeal Shock Wave Therapy in Keloids and Hypertrophic Scars: A Systematic Review.
Gili N, Micallef Stafrace K, Laybats F, Mifsud T. · Cureus · 2024
Open the publication record or available full-text files.
Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →